Newer renin-angiotensin-aldosterone system blocker combinations: Is there an advantage?

Current Opinion in Nephrology and Hypertension

Volumn 20, Issue 5, 2011, Pages 471-475

  Lazich, Ivana ^a   Bakris, George L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

cardiovascular; combination therapy; hypertension; kidney

Indexed keywords

ALDOSTERONE ANTAGONIST; ALISKIREN; AMLODIPINE; AMLODIPINE BESYLATE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; AZILSARTAN; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; IRBESARTAN; NONDIHYDROPYRIDINE; OLMESARTAN; OLMESARTAN MEDOXIMIL; RENIN INHIBITOR; TELMISARTAN; UNCLASSIFIED DRUG; VALSARTAN;

BLOOD PRESSURE REGULATION; COMBINATION CHEMOTHERAPY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; HUMAN; HYPERTENSION; MONOTHERAPY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTOLIC BLOOD PRESSURE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG COMBINATIONS; HUMANS; HYPERTENSION; RENIN; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 80051802107     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3283495819     Document Type: Review

References (39)

1. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123:933-944.
2. Franco OH, Peeters A, Bonneux L, De LC. Blood pressure in adulthood and life expectancy with cardiovascular disease in men and women: life course analysis. Hypertension 2005;46:280-286. (Pubitemid 41099158)
3. Yoon SS, Ostchega Y, Louis T. Recent trends in the prevalence of high blood pressure and its treatment and control, 1999-2008. NCHS. Data Brief. 2010, 1-8.
4. Izzo JL, Black HR, Sica DA. Systemic hemodynamics and regional blood flow regulation. In IzzoJL, Black HR, editors. Hypertension primer: the essentials of high blood pressure: basic science and clinical management. 4th ed. Council for High Blood Pressure Research (American Heart Association). Philadelphia, PA: Lippincott, Williams & Wilkins; 2008. pp. 36-44.
5. Sica DA. Rationale for combination therapy in the treatment of hypertension. J Renin Angiotensin Aldosterone Syst 2002;3:63-65. (Pubitemid 34966174)
6. Lambers Heerspink HJ, Perkovic V, de Zeeuw D. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. J Hypertens 2009;27:2321-2331.
7. Gupta M, Honos GN, Velazquez EJ, et al. Evidence for the efficacy of ARBs across the cardiovascular continuum. Curr Med Res Opin 2010;26:1203-1218.
8. Katragadda S, Arora RR. Role of angiotensin-converting enzyme inhibitors in vascular modulation: beyond the hypertensive effects. Am J Ther 2010;17:e11-e23.
9. Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens 2010;4:42-50. This article summarizes the most current recommendations and rationale for combination therapy in the management of hypertension.
10. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252. (Pubitemid 37553153)
11. Zannad F. Managing hypertension: a question of STRATHE. J Hum Hypertens 2005;19(Suppl 1):S3-S7. (Pubitemid 40946028)
12. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J 2003;326:1427.
13. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11, 000 participants from 42 trials. Am J Med 2009;122:290-300.
14. Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension 2009;53:646-653.
15. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-719. (Pubitemid 47176510)
16. Weiss RJ, Sandall PG, Chrysant SG. Perindopril/hydrochlorothiazide combination in hypertensive patients unresponsive to hydrochlorothiazide alone: a double-blind, multicenter study. Am J Ther 1994;1:125-132.
17. Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. A large multicenter study. Lisinopril-Hydrochlorothiazide Group. Arch Intern Med 1994;154:737-743. (Pubitemid 24115660)
18. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007;25:217-226. (Pubitemid 44885684)
19. Kjeldsen SE, Os I, Hoieggen A, et al. Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs 2005;5:17-22.
20. Asmar R, Oparil S. Comparison of the antihypertensive efficacy of irbesartan/HCTZ and valsartan/HCTZ combination therapy: impact of age and gender. Clin Exp Hypertens 2010;32:499-503.
21. Parati G, Schumacher H, Bilo G, Mancia G. Evaluating 24-h antihypertensive efficacy by the smoothness index: a meta-analysis of an ambulatory blood pressure monitoring database. J Hypertens 2010;28:2177-2183. This meta-analysis gives further insight into the importance of continuous BP lowering with the combination medication approach.
22. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010;375:938-948.
23. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-tovisit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010;375:895-905.
24. Mancia G, Bombelli M, Facchetti R, et al. Long-term prognostic value of blood pressure variability in the general population: results of the Pressioni Arteriose Monitorate e Loro Associazioni Study. Hypertension 2007;49:1265-1270. (Pubitemid 46809367)
25. White WB, Weber MA, Sica D, et al. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension 2011;57:413-420.
26. Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) 2011;13:81-88.
27. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-358. (Pubitemid 43740274)
28. Dorsch MP, Gillespie BW, Erickson SR, et al. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension 2011;57:689-694. This study provides imortant additional evidence for the implementation of chlorthalidone instead of hydrochlorothiazide in hypertensive patients.
29. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428.
30. Bakris GL, Weir MR. Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich) 2003;5:202-209. (Pubitemid 37428137)
31. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998;54:1283-1289. (Pubitemid 28449916)
32. Andreadis EA, Tsourous GI, Marakomichelakis GE, et al. High-dose monotherapy vs. low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension. J Hum Hypertens 2005;19:491-496. (Pubitemid 40767186)
33. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007;29:563-580. (Pubitemid 47028551)
34. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30:587-604. (Pubitemid 351680489)
35. Moen MD. Telmisartan/amlodipine: single-pill combination in hypertension. Am J Cardiovasc Drugs 2010;10:401-412.
36. Brown MJ, McInnes GT, Papst CC, et al. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 2011;377:312-320. This recent trial gives further support for combination therapy implementation as initial approach in hypertensive patients with improved blood pressure outcomes in this group at the end of the trial compared with sequential therapy group.
37. Ram CV. Olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide triple combination for hypertension. Expert Rev Cardiovasc Ther 2011;9:9-19.
38. Deeks ED. Amlodipine/valsartan/hydrochlorothiazide: fixed-dose combination in hypertension. Am J Cardiovasc Drugs 2009;9:411-418.
39. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009;24:1663-1671.